Search

Your search keyword '"Lipids"' showing total 2 results
2 results on '"Lipids"'

1. Contemporary Management of Dyslipidemia.

Author

Ferraro, Richard A., Leucker, Thorsten, Martin, Seth S., Banach, Maciej, Jones, Steven R., and Toth, Peter P.

Subjects
*HYPERLIPIDEMIA treatment, *CARDIOVASCULAR disease prevention, *DRUG therapy for hyperlipidemia, *THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of omega-3 fatty acids, *STATINS (Cardiovascular agents), *CARDIOVASCULAR diseases risk factors, *TRIGLYCERIDES, *ANTILIPEMIC agents, *HOMOZYGOUS familial hypercholesterolemia, *CLOFIBRIC acid, *LDL cholesterol, *DIET, *MEDICAL protocols, *EZETIMIBE, *HEALTH behavior, *DRUGS, *DRUG monitoring, *PATIENT compliance, *MEDICAL research, *DISEASE management, *LIPIDS, *ENZYME inhibitors, *BEHAVIOR modification, *EXERCISE therapy
Abstract

The treatment of dyslipidemia continues to be a dynamic and controversial topic. Even the most appropriate therapeutic range for lipid levels—including that of triglycerides and low-density lipoprotein cholesterol—remain actively debated. Furthermore, with ever-increasing options and available treatment modalities, the management of dyslipidemia has progressed in both depth and complexity. An understanding of appropriate lipid-lowering therapy remains an essential topic of review for practitioners across medical specialties. The goal of this review is to provide an overview of recent research developments and recommendations for patients with dyslipidemia as a means of better informing the clinical practice of lipid management. By utilizing a guideline-directed approach, we provide a reference point on optimal lipid-lowering therapies across the spectrum of dyslipidemia. Special attention is paid to long-term adherence to lipid-lowering therapies, and the benefits derived from instituting appropriate medications in a structured manner alongside monitoring. Novel therapies and their impact on lipid lowering are discussed in detail, as well as potential avenues for research going forward. The prevention of cardiovascular disease remains paramount, and this review provides a roadmap for instituting appropriate therapies in cardiovascular disease prevention. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

2. Clinical experience with simvastatin compared with cholestyramine

Author

M. J. T. M. Mol, J. C. Koningsberger, M. G. A. Baggen, D. W. Erkelens, M. Kettner, and J. J. Van Doormaal

Subjects
Adult, Male, Simvastatin, Apolipoprotein B, Cholestyramine Resin, Pharmacology, Transaminase, Hyperlipoproteinemia Type II, chemistry.chemical_compound, medicine, Humans, Pharmacology (medical), Lovastatin, Triglycerides, Aged, Cholestyramine, biology, Triglyceride, business.industry, Cholesterol, Anticholesteremic Agents, Cholesterol, HDL, Cholesterol, LDL, Middle Aged, Lipids, Apolipoproteins, chemistry, HMG-CoA reductase, biology.protein, lipids (amino acids, peptides, and proteins), Female, business, medicine.drug
Abstract

Simvastatin (MK733), derived from lovastatin by substituting CH3 for H at the 2' position, is a potent hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Its cholesterol-lowering effect in 40 patients with heterozygous familial hypercholesterolaemia was more pronounced (an LDL-cholesterol reduction of 43%) than that of cholestyramine monotherapy in a matched group of 20 patients (30% reduction). The combination of the 2 drugs for 50 patients who tolerated cholestyramine was even more effective (a 54% reduction of LDL-cholesterol). The other changes were as follows: total cholesterol (simvastatin [S] -36%, cholestyramine [C] -23%, both drugs in combination [S + C] -45%); HDL-cholesterol (S +16%, C +9%, S + C +20%); triglyceride (S -21%, C +11%, S + C -17%); and the apolipoprotein B/apolipoprotein A ratio (S -51%, C -39%, S + C -67%). Cholestyramine caused more gastrointestinal adverse effects (12 of 20 patients), whereas a transaminase increase was seen both with cholestyramine (2 of 20 patients) and simvastatin (3 of 40 patients) and with the combination (6 of 50 patients). Treatment with simvastatin decreases the atherogenic potential of plasma more than cholestyramine monotherapy and causes fewer adverse effects. For those patients who tolerate cholestyramine, the combination of the drugs is even more potent.

Published
1988

Catalog

Books, media, physical & digital resources
See catalog results